Xlife Sciences AG / Key word(s): IPO/Merger Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4 17.07.2025 / 07:00 CET/CEST The filing demonstrates continued momentum in VERAXA’s public market journey and billion-dollar valuation Zurich, 17th of July 20 [ … ]

Xlife Sciences AG / Key word(s): AGMEGM Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025 24.06.2025 / 18:00 CET/CEST Zurich, 24th of June 2025: At today’s Annual General Meeting of Xlife Sciences AG (SIX: XLS), all proposals of the Board of Directors were approved. A total of 3’181’966 voting  [ … ]

Xlife Sciences AG / Key word(s): Alliance/Partnership Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia 16.06.2025 / 16:00 CET/CEST Zurich, 16th of June 2025: Xlife Sciences AG («Xlife Sciences»SIX: XLS), a Swiss-based incub [ … ]

Xlife Sciences AG / Key word(s): Alliance/Partnership Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets 13.06.2025 / 17:42 CET/CEST Zurich, 13th of June 2025: Xlife Sciences AG («Xlife Sciences», SIX: XLS), a Swiss-based [ … ]

Xlife Sciences AG / Key word(s): Alliance/Partnership Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company Firstgene Life Sciences and Hovione in the Field of Gene Therapy 06.05.2025 / 07:00 CET/CEST Zurich, 6th of May 2025: Xlife Sciences AG («Xlife Sciences»; SIX:XLS) is proud to announce a st [ … ]